$7.620
+0.226 (+2.97%)At close
NLSP Comparative Benchmarking
In the context of the broader market, NLSP competes directly with industry leaders such as ONCO and KALA. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, NLSP's gross margin of N/A stands against ONCO's 25.13% and KALA's N/A. Such benchmarking helps identify whether NLS Pharmaceutics AG is trading at a premium or discount relative to its financial performance.
Financials
No data
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.